Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alzamend Neuro, Inc. - Common Stock
(NQ:
ALZN
)
1.160
+0.010 (+0.87%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Alzamend Neuro, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Alzamend Neuro And 3 Other Stocks Under $3 Insiders Are Buying
January 10, 2024
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 19, 2023
Via
Benzinga
ALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024
December 18, 2023
ALZN stock results show that Alzamend Neuro beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
ALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024
December 18, 2023
Alzamend Neuro just reported results for the second quarter of 2024.
Via
InvestorPlace
EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year
December 11, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for
Via
Benzinga
Exposures
Product Safety
Why Ault Alliance Are Rocketing Today
July 12, 2023
Ault Alliance Inc (AMEX: AULT) shares are trading exponentially higher by over 147% after the company stated that
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 30, 2023
Via
Benzinga
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 21, 2023
Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 21, 2023
Via
Benzinga
Why Symbotic Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
November 21, 2023
Shares of Symbotic Inc. (NASDAQ: SYM) surged in pre-market trading after the company reported better-than-expected fourth-quarter sales results.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
November 21, 2023
It's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
November 20, 2023
Via
Benzinga
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 20, 2023
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
November 20, 2023
Via
Benzinga
EXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder Study
November 20, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) has received a "Study May Proceed" letter from the FDA for the initiation of study AL001-MDD01, a Phase 2A clinical study of AL001 for
Via
Benzinga
Exposures
Product Safety
EXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug Candidate
November 13, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA for the initiation of study AL001-PTSD01, a Phase 2A plasma/brain pharmacokinetics study of...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 08, 2023
Via
Benzinga
Dow Surges Over 500 Points; Western Digital Announces Plan To Split Into Two Companies
October 30, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 500 points on Monday. The Dow traded up 1.67% to 32,959.68 while the NASDAQ rose 1.25% to 12,800.95. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crude Oil Falls Over 3%; Miromatrix Medical Shares Spike Higher
October 30, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up 1.14% to 32,788.73 while the NASDAQ rose 0.98% to 12,766.33. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 30, 2023
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.
Via
Benzinga
Why Alzamend Neuro (ALZN) Stock Is Nosediving Today
October 30, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) shares are trading lower by 31.2% to $0.12 Monday morning after the company announced a reverse stock split. What Happened?
Via
Benzinga
Nasdaq Gains Over 1%; McDonald's Reports Upbeat Earnings
October 30, 2023
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 250 points on Monday. Following the market opening Monday, the Dow traded up 0.85% to 32,695.89 while the NASDAQ rose...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder
October 23, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-MDD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for...
Via
Benzinga
Exposures
Product Safety
EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder
October 02, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) received the FDA's "Study May Proceed" letter to initiate study AL001-BD01, a Phase 2A clinical study of AL001 for bipolar disorder type 1. The company expects the...
Via
Benzinga
NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying
September 27, 2023
The Dow Jones closed lower by around 388 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 20, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
September 08, 2023
Via
Benzinga
EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder
August 30, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-BD01, a Phase 2A study of AL001 for bipolar disorder.
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 15, 2023
Via
Benzinga
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
July 07, 2023
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.